DGX stock forecast, quote, news & analysis

Key Takeaways

• Quest Diagnostics shares pulled back roughly 4.6% over the trailing 30 days, from about $246.45 to $235.00, after touching a 52-week high of $248.84 in mid-September.
• Second-quarter 2026 results were strong: adjusted EPS of $3.12 rose 19.1% year over year, and revenue of $3.04 billion grew 10.2%, with requisition volume up 13.1%.
• Management raised its full-year 2026 outlook to revenue of $11.95–$12.05 billion and adjusted EPS of $11.05–$11.25.
• The stock trades near the high end of its five-year valuation range at roughly 20.3x forward earnings, while adjusted operating margin declined 40 basis points to 16.5% in the latest quarter.
• Reimbursement uncertainty, cost inflation, and long-term debt of $5.63 billion are the main counterweights to otherwise robust testing demand.

Current Market Snapshot

Quest Diagnostics (DGX) has been one of the steadier names in healthcare services in 2026, benefiting from broad-based demand across physician, hospital, and consumer channels. The stock rallied through the first half of the year and set a 52-week high of $248.84 in mid-September before giving back some gains. With a beta near 0.55 and a dividend yield of about 1.5%, Quest is often treated as a relatively defensive holding within the diagnostics group, though its forward earnings multiple now sits above its five-year median of roughly 16.2x. After a multi-month advance, the shares have consolidated as investors weigh strong volume growth against thinner margins, higher costs, and lingering Medicare reimbursement questions.

Quest Diagnostics Business Overview and Competitive Position

Quest Diagnostics is a leading provider of diagnostic information services in the United States, operating a national network of laboratories and patient service centers alongside in-office phlebotomy and mobile collection. Its Diagnostic Information Services segment generates nearly all of the company's revenue, serving physicians, hospitals, health plans, employers, and consumers under brands including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.

The company competes directly with peers such as Labcorp (LH) on scale, turnaround time, access, and clinical breadth. Quest's growth strategy centers on advanced diagnostics across brain health, cardiometabolic and endocrine testing, autoimmune disease, oncology, and women's and reproductive health, complemented by a growing consumer platform, QuestHealth.com, and collaborations with wearable and wellness brands. Strategic hospital partnerships such as Co-Lab Solutions with Corewell Health and a kidney-care collaboration with Fresenius Medical Care have broadened its channel mix, while automation and AI initiatives under the Invigorate program support productivity goals.

Recent Developments Driving DGX

The most significant recent catalyst remains the company's second-quarter results, reported in late July, which showed adjusted EPS up 19.1% and revenue up 10.2% year over year, driven by a 13.1% increase in requisition volume. Management followed with a raised 2026 outlook, now projecting revenue of $11.95–$12.05 billion and adjusted EPS of $11.05–$11.25, reflecting stronger testing demand and improved earnings conversion.

In the weeks that followed, the focus shifted to valuation and analyst positioning. Barclays raised its price target to $260 from $250 with an Overweight rating, while Leerink Partners lifted its target to $265 from $254. Evercore ISI took a more cautious view, trimming its target to $235 from $240 while maintaining an In Line rating. On the product front, Quest highlighted data published in The Journal of Molecular Diagnostics showing high accuracy for its Haystack MRD liquid biopsy in detecting residual disease in colorectal and other solid tumors. The pullback from September's high occurred against this backdrop, as investors balanced improving fundamentals against a fuller valuation and cost-driven margin compression.

Trending AI Robots

For traders seeking a systematic edge across the market, Tickeron's Trending AI Robots page offers a curated view of its top-performing automated trading strategies. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only the most relevant and highest-performing bots are surfaced in this dedicated section. Each bot differs in its underlying strategy, trading timeframe, and performance metrics, allowing users to filter for approaches that match their own objectives. Whether the goal is to identify momentum setups, track mean-reversion signals, or follow longer-term trends, the platform provides a data-driven way to review algorithmic strategies across a broad universe of stocks. Exploring the Trending AI Robots section can help investors evaluate how AI-driven signals compare with their own analysis.

2026 Outlook and What Investors Should Watch

Looking ahead, the central question is whether Quest's volume-led growth can continue to offset margin and reimbursement pressures. The next quarterly earnings report, scheduled for late October, will be closely watched for updates on requisition trends, revenue per requisition, and the impact of the Corewell and Fresenius mix. Management has flagged a roughly 30-basis-point revenue headwind in 2026 from the expiration of enhanced Affordable Care Act exchange subsidies, with the possibility of a larger second-half effect.

Investors should also monitor the PAMA survey process and any changes to Medicare lab rates, which could shape the 2027 pricing environment. Execution on Project Nova, the multi-year order-to-cash transformation, and the pace of automation-driven savings under the Invigorate program will be important for margin recovery. Finally, continued traction in advanced diagnostics, including the AD-Detect blood test for Alzheimer's disease and the Haystack MRD platform, along with consumer and hospital partnerships, represents the primary longer-term growth lever. Elevated debt and a premium valuation leave less room for missteps if volume growth or margin recovery disappoints.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations